1-4 of 4
Harald Ballo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

Mathias J. Rummel, MD, Norbert Niederle, Georg Maschmeyer, MD, G.-Andre Banat, MD, PhD, MBA, Ulrich von Grünhagen, MD, PhD, Chrisoph Losem, MD, PhD, Dorothea Kofahl-Krause, Gerhard Heil, MD, Manfred Welslau, Christina Balser, Ulrich Kaiser, MD, Eckhart Weidmann, Heinz A. Duerk, MD, PhD, Harald Ballo, Martina Beate Stauch, MD, Fritz Roller, Juergen Barth, Axel Hinke, Alexander C. Burchardt, MD, Wolfram Brugger
Journal: Blood
Blood (2012) 120 (21): 2724.
https://doi.org/10.1182/blood.V120.21.2724.2724
Published: 2012
Journal Articles

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

Mathias J Rummel, MD, PhD, Ulrich Kaiser, MD, Christina Balser, Martina Beate Stauch, Wolfram Brugger, MD, PhD, Manfred Welslau, Norbert Niederle, Christoph Losem, Harald Ballo, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, MD, Julia Vereschagina, Axel Hinke, Juergen Barth
Journal: Blood
Blood (2010) 116 (21): 856.
https://doi.org/10.1182/blood.V116.21.856.856
Published: 2010
Journal Articles

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke, Wolfram Brugger
Journal: Blood
Blood (2009) 114 (22): 405.
https://doi.org/10.1182/blood.V114.22.405.405
Published: 2009
Journal Articles

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Mathias J Rummel, Ulrich von Gruenhagen, Norbert Niederle, Harald Ballo, Eckhart Weidmann, Manfred Welslau, Gerhard Heil, Christina Balser, Heinz A Duerk, Martina Stauch, Dorothea Kofahl-Krause, Ulrich Kaiser, Wolfgang Knauf, Wolfram Brugger, MD
Journal: Blood
Blood (2008) 112 (11): 2596.
https://doi.org/10.1182/blood.V112.11.2596.2596
Published: 2008